Impact of coexisting overactive bladder in Medicare patients with osteoporosis

Caplan, Eleanor O.; Abbass, Ibrahim M.; Suehs, Brandon T.; Ng, Daniel; Gooch, Katherine; Kirby, Cindy; Abbott, Paul

doi:10.1016/j.archger.2017.11.005

Cited by 5 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the case cohort, an antidepressant medication prescription claim had to occur within 1 month prior or 1 month following the OAB index date; for the control cohort, within 1 month prior or 1 month following the proxy index date. Patients with OAB were identified using criteria similar to those of previously published studies of patients with OAB [ 9 , 10 ]. Included were patients with the presence of at least one inpatient or two outpatient claims for an OAB diagnosis (International Classification of Diseases [ICD]-9 or ICD-10; Appendix 1 in ESM) or a prescription claim for a medication indicated almost exclusively to treat OAB (darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, trospium, mirabegron; patients who may have been treated for other indications of these medications (i.e., neurogenic bladder) were excluded).…”

Section: Methodsmentioning

confidence: 99%

“…In addition, OAB has been found to affect twice as many women as men [ 8 ]. It has been previously shown that OAB is a cost multiplier when comorbid with conditions like dementia [ 9 ] and osteoporosis [ 10 ]. Several biological and epidemiological studies have shown an association between depression and urinary incontinence, a symptom of OAB [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Increased Healthcare Resource Utilization and Direct and Indirect Costs in Patients with Depression and Comorbid Overactive Bladder: Evidence From a Retrospective, Matched Case–Control Cohort Analysis

et al. 2020

View full text Add to dashboard Cite

Introduction This study sought to compare healthcare resource utilization (HCRU), costs, and workplace productivity among patients with depression, with and without overactive bladder (OAB). Methods This retrospective, case–control cohort analysis compares HCRU, costs, and workplace productivity among propensity score matched patients with depression and OAB (case cohort) and patients with depression without OAB (control cohort). Patients were aged 18 years or older, insured/on Medicare, and had diagnosed depression and an antidepressant medication claim pre index. First OAB-related event was index for cases; controls were assigned a proxy (study period 12 months). Comparisons of HCRU and costs and regression models assessed the relationship between OAB and costs. For the workplace productivity subset analyses cases and controls were balanced on baseline covariates for the short-term disability analyses but as they were unbalanced for the absentee analyses, multivariate regression analyses were used for this subset. Results The study criteria were met by 39,085 cases and 308,736 controls, from which, 37,997 patients were successfully matched 1:1 (mean age 55 years; 81% female). Most depression-related HCRU measures were similar across cohorts; however, outpatient visits, ER visits, and number of unique depression medications were significantly higher (all p < 0.05) among cases. Cases also had 13% higher total depression-related costs ( p < 0.0001). Total mean (standard deviation [SD]) depression-related costs were $1796 ($4235) for cases versus $1597 ($3863) for controls ( p < 0.0001). For workplace productivity (absentee data: cases [ n = 686], controls [ n = 642]; short-term disability data: cases [ n = 4395], controls [ n = 4433]) absentee outcomes were similar across cohorts. However, a higher percentage of cases used short-term disability benefits compared to controls (21.3% versus 16.9%; p < 0.0001) and cases experienced more case days (11.0 versus 8.6 mean days) and received higher mean payments than controls ($1226 versus $1033; p < 0.0001) in this subset. Conclusions OAB was associated with 13% higher depression-related costs and 4.4% more cases used short-term disability benefits. Electronic Supplementary Material The online version of this article (10.1007/s12325-020-01485-w) contains supplementary material, which is available to authorized users.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Increased Healthcare Resource Utilization and Direct and Indirect Costs in Patients with Depression and Comorbid Overactive Bladder: Evidence From a Retrospective, Matched Case–Control Cohort Analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The costs of LUTS were explored in several countries. The United States had the highest number of studies (n = 15, 33.3%), [7][8][9][10][11][12][13][14][15][16][17][18][19][20] however, Germany (n = 3, 6.7%), [21][22][23] Italy (n = 3, 6.7%), [24][25][26] and South Korea (n = 3, 6.7%) [27][28][29] contributed proportionally high. Several counties only had one-two studies, including Australia, Denmark, Brazil, Canada, China, France, Spain, the United Kingdom, Hungary, Ireland, Poland, Sweden, Switzerland, and Taiwan.…”

Section: Included Articlesmentioning

confidence: 99%

The cost of lifelong LUTS—A systematic literature review

Holm‐Larsen,

Van den Ende,

Wendelboe

et al. 2024

Neurourology and Urodynamics

View full text Add to dashboard Cite

BackgroundLower urinary tract symptoms (LUTS) are highly prevalent and very bothersome. To support the best possible allocation of health care resources and to avoid unnecessary expenditures, it is important to understand and quantify the wide‐ranging health care costs affecting people suffering from LUTS. We aimed at creating a foundation for exploring the cost of LUTS.MethodIn this systematic literature review, we explored the costs of illness of the LUTS umbrella. We used the online literature review tool Silvi.ai for transparent decision‐making and literature management.ResultsA total of 1821 original articles were screened. Forty had explored the cost of illness of a LUTS disease since 2013. The studies were conducted in 18 countries. A number of different study designs were applied, including both retrospective and prospective studies. In total, seven LUTS indications were explored. None of them focused on lifelong LUTS. None of them were conducted in infants or children. Eighty‐two percent were conducted in adults and 18% in frail elderly. Most cost of illness studies focused on the cost of hospitalization and use of medicine.ConclusionWe have created the groundwork for understanding the cost of LUTS illness. To fully understand the cost of illness of lifelong LUTS, the main gap in research is to investigate the cost of LUTS in infants and children.

show abstract